var data={"title":"Society guideline links: Myeloproliferative disorders","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Society guideline links: Myeloproliferative disorders</div><p class=\"disclosureLink\"></p><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H2939616756\"><span class=\"h1\">Introduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.</p><p>The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.</p><p class=\"headingAnchor\" id=\"H900412216\"><span class=\"h1\">International</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nature.com/articles/s41408-018-0054-y.pdf&amp;token=gdEMl/3RV4q6xsBHuH4h8hRSJG/ykoljM3r4sbP1aavkhjkG9Yf1JSOTZjH8kAZtoQpYzcE3FzBgLScJ2O9O6g==&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and indepth discussion</a> (published 2018)</p><p/><p class=\"headingAnchor\" id=\"H3769167777\"><span class=\"h1\">United States</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf&amp;token=wEsKVFvqlKzpT+qOtddW/0EI3b9twjod2/LFKUj9NsU4ox9FR7jHnAHXjF2BNuwb00+jGuvwHKL3GIkZ+4/Wha8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology &ndash; Myeloproliferative neoplasms</a> (2017)</p><p/><p class=\"headingAnchor\" id=\"H1457214344\"><span class=\"h1\">Europe</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nature.com/articles/leu2015233.pdf&amp;token=gdEMl/3RV4q6xsBHuH4h8hRSJG/ykoljM3r4sbP1aaueSFHhZMzTWxw1O4Q46HLAhy6jItUcLyw66NTIzkSQrg==&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet (ELN): A consensus process for the indication and management of allogeneic stem cell transplantation in primary myelofibrosis</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.esmo.org/Guidelines/Haematological-Malignancies/Philadelphia-Chromosome-Negative-Chronic-Myeloproliferative-Neoplasms&amp;token=+hob8jn/j1K1EHQL3gZmbNV8CZOW/3L1o9wqCtoD/qOVZn1LyPrtrhH066J8qnNmhJCqAvlX5hdxpljZLf6npR6OMkFZyvhMTVUUT77sUiwNLxFujD3bI2mEnQzANn6G3pt9BqpG3zLm/x7gCSo7Og==&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment and follow-up of Philadelphia chromosome-negative chronic myeloproliferative neoplasms</a> (2015)</p><p/><p class=\"headingAnchor\" id=\"H4017010513\"><span class=\"h1\">United Kingdom</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta386&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dN5vr9L4fMULP8tx0oKuQAy&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">National Institute for Health and Care Excellence (NICE): Technology appraisal guidance on ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12985/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGCTPnFTAhgsL2ZMSfS9ze1A==&amp;TOPIC_ID=116776\" target=\"_blank\" class=\"external\">British Society for Haematology (BSH): Use of JAK inhibitors in the management of myelofibrosis &ndash; A revision of the British Committee for Standards in Haematology guidelines for investigation and management of myelofibrosis 2012</a> (published 2014)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 116776 Version 2.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H2939616756\" id=\"outline-link-H2939616756\">Introduction</a></li><li><a href=\"#H900412216\" id=\"outline-link-H900412216\">International</a></li><li><a href=\"#H3769167777\" id=\"outline-link-H3769167777\">United States</a></li><li><a href=\"#H1457214344\" id=\"outline-link-H1457214344\">Europe</a></li><li><a href=\"#H4017010513\" id=\"outline-link-H4017010513\">United Kingdom</a></li></ul></div>","javascript":null}